國家衛生研究院 NHRI:Item 3990099045/7951
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 857826      在线人数 : 835
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/7951


    题名: SLC14A1 down-regulation is associated with poor clinical outcome in patients with urothelial carcinoma of upper urinary tracts and urinary bladder
    作者: Liang, PI;Li, CF
    贡献者: National Institute of Cancer Research
    摘要: Background: Urothelial carcinoma (UC) is a common cancer in industrialized country. UC of urinary bladder (UCUB) and of upper urinary tract (UCUT) may share similar tumorigenesis. Previously, genome-wide association studies identifi ed that genetic variation of solute carrier family 14 transporters, member 1 (SLC14A1) is associated with bladder cancer development. By using public domain datasets and our well-characterized cohort, we intended to analyze the association of SLC14A1 expression in UCUB and UCUT.Design: Two datasets from GEO (GSE31684 and GSE32894) were selected and analyzed to examine the signifi cance of SLC14A1 transcript expression in relation to primary tumor (pT) status. SLC14A1 transcript levels were further validated by using Quantigene assay in 35 and 40 UBUC and UTUC cases respectively, and were further correlated with various clincopathological factors. SLC14A1 immunostain was performed on 340 cases of UCUT and 295 cases of UBUC and interpreted by using H-score. The immunoexpression was then correlated with clinicopathological features, disease-specifi c survival (DSS), and metastasis-free survival (MeFS).Results: Validation of SLC14A1 transcript in public domain datasets showed a stepwise down-regulation during UCUB progression, which is also confi rm by using Quantigene assay in our cohort. In the immunohistochemical study, loss of SLC14A1 expression in both groups of UCs signifi cantly associated with advanced pT stage (both p <0.001), lymph node metastasis (both p <0.001), high histological grade (both p <0.001), vascular invasion (both p <0.001), perineurial invasion (UCUT, p =0.002; UCUB, p =0.021), and frequent mitosis (both p =0.003). Loss of SLC14A1 expression also independently predicted poor DSS (UCUT p =0.033; UCUB p =0.005) and MeFS (UCUT p =0.012; UCUB p =0.031) in both groups of patients.Conclusions: SLC14A1 down-regulation is associated with advanced tumor stage and conferred poorer clinical outcome, justifying that SLC14A1 is a potential prognostic biomarker of UC.
    日期: 2014-02
    關聯: Laboratory Investigation. 2014 Feb;94(S1):245A.
    Link to: http://dx.doi.org/10.1038/labinvest.2014.23
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0023-6837&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000331155801225
    显示于类别:[其他] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000331155801225.pdf159KbAdobe PDF500检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈